Infectious Disease Research Centre?

The Infectious Disease Research Centre is a biomedical research institution founded in Cambridge in 1968 under the direction of James Halloway, a British immunologist, to pursue the development of serum therapy as a systemic treatment for bacterial infection. Its establishment followed the recognition, through the 1960s, that the azo drugs—the only reliable chemical class for systemic bacterial kill—were approaching the limits of their clinical efficacy as bacteria developed resistance and side effects accumulated with prolonged use. The Centre's founding coincided with early results from Dorothy Umezaki's Japanese laboratory showing that refined serum preparations could achieve measurable bacterial kill in animal models of sepsis.

The Cambridge facility was constructed at a cost of £1.2 million over a three-year period, sited near the Cambridge Clinical School to enable close cooperation with clinical bacteriology and hospital medicine. The building's design reflected the precepts of asepsis maximalism: it contained three separate laboratory suites with staged entry controls, separate air handling systems for each level of biological containment, and autoclave and incineration equipment installed directly into the walls to prevent carriage of contaminated materials through corridors. This physical embedding of sterility protocols was unusual for the era, as most research hospitals had not yet rebuilt to such stringent standards.

From 1969 to 1975, the Centre employed between 14 and 22 research staff at any given time, growing from an initial team of five bacteriologists and two animal-care specialists. Halloway recruited heavily from German and Swiss universities; former assistants of Richard Reinhardt at the Institute for the History of Bacteriology in Berlin made up nearly a third of the senior staff by 1973. The Centre also hosted visiting scholars from the Pasteur Institute, which had pivoted toward serum therapy research after 1928 and maintained the world's largest colonial collections of pathogenic bacterial strains.

The Centre's laboratories focused on three parallel problems: the purification and concentration of therapeutic serum fractions using ion-exchange chromatography; the production of high-titre serum in large animal populations through controlled immunization protocols; and the measurement of clinical efficacy in human trials. The third task drove much of the Centre's innovation in statistical methods in clinical bacteriology and their application to serum therapy trials, as passive immunotherapy produced more variable outcomes than the azo drugs and required new frameworks for interpreting dose-response and time-course data. Halloway's team developed the "successive cohort method" for serum therapy trials, now standard in the field, which allowed clinicians to adjust dosing between patient groups mid-trial without invalidating the statistical conclusions.

The Cambridge Centre's relationship to Umezaki's parallel work in Tokyo was collaborative but occasionally contentious. Both laboratories produced significant refinements to serum fraction preparation simultaneously between 1973 and 1976; the question of priority in certain immunofraction techniques remains contested in the scholarly literature. However, the two groups maintained regular correspondence and coordinated their clinical trial protocols, a relationship that accelerated the licensing of the Halloway-Umezaki method by national regulatory bodies between 1979 and 1982.

By 1980, the Cambridge Centre had expanded to three buildings and a staff of forty-three. Its success in documenting clinical efficacy for serum therapy led to a shift in its institutional focus: it became a centre for training other institutions' bacteriologists in serum production and clinical trial design, rather than a primary research facility. From 1982 onward, much of its budget derived from fees paid by pharmaceutical manufacturers seeking to develop their own serum therapy programmes. The Centre's archives, including Halloway's correspondence with international colleagues and the raw data from early serum therapy trials, passed to the Archives of the Institute for the History of Bacteriology in Berlin upon the Centre's closure in 2003, following Halloway's retirement.

The physical plant of the original Cambridge building survives, now occupied by a private diagnostic laboratory specializing in bacterial serum-susceptibility testing. The tiered air-handling systems, installed in the 1970s at great expense, remain largely intact, though no longer in active use.